Page last updated: 2024-10-24

carmustine and Bare Lymphocyte Syndrome

carmustine has been researched along with Bare Lymphocyte Syndrome in 2 studies

Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zielske, SP1
Reese, JS1
Lingas, KT1
Donze, JR1
Gerson, SL1
Cai, S1
Hartwell, JR1
Cooper, RJ1
Juliar, BE1
Kreklau, E1
Abonour, R1
Goebel, WS1
Pollok, KE1

Other Studies

2 other studies available for carmustine and Bare Lymphocyte Syndrome

ArticleYear
In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning.
    The Journal of clinical investigation, 2003, Volume: 112, Issue:10

    Topics: Animals; Antigens, CD34; Antineoplastic Agents; Carmustine; Gene Transfer Techniques; Genetic Vector

2003
In vivo effects of myeloablative alkylator therapy on survival and differentiation of MGMTP140K-transduced human G-CSF-mobilized peripheral blood cells.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2006, Volume: 13, Issue:5

    Topics: Animals; Antineoplastic Agents, Alkylating; Blood Cells; Carmustine; Cell Differentiation; Cell Surv

2006